Bank of New Hampshire Has $529,000 Stock Position in Amgen Inc. (NASDAQ:AMGN)

Bank of New Hampshire cut its position in Amgen Inc. (NASDAQ:AMGN) by 19.8% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 1,836 shares of the medical research company’s stock after selling 454 shares during the quarter. Bank of New Hampshire’s holdings in Amgen were worth $529,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. OFI Invest Asset Management bought a new position in shares of Amgen during the 3rd quarter worth approximately $26,000. Briaud Financial Planning Inc purchased a new stake in shares of Amgen during the third quarter valued at approximately $26,000. BOK Financial Private Wealth Inc. bought a new stake in Amgen during the fourth quarter worth $29,000. Providence Capital Advisors LLC purchased a new position in Amgen in the third quarter worth $30,000. Finally, Planned Solutions Inc. bought a new position in Amgen in the 4th quarter valued at $30,000. 76.50% of the stock is owned by institutional investors.

Amgen Price Performance

Shares of AMGN traded down $3.63 during midday trading on Thursday, hitting $269.38. 1,760,647 shares of the company traded hands, compared to its average volume of 2,827,028. The firm has a 50 day moving average of $275.77 and a 200-day moving average of $281.55. Amgen Inc. has a 52 week low of $211.71 and a 52 week high of $329.72. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. The stock has a market cap of $144.49 billion, a price-to-earnings ratio of 21.86, a PEG ratio of 2.55 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, topping the consensus estimate of $4.66 by $0.05. The company had revenue of $8.20 billion during the quarter, compared to analyst estimates of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The firm’s revenue was up 19.8% on a year-over-year basis. During the same quarter last year, the business posted $4.09 earnings per share. On average, analysts forecast that Amgen Inc. will post 19.42 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be given a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 3.34%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is currently 72.06%.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on AMGN. SVB Leerink downgraded shares of Amgen from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $324.00 to $318.00 in a report on Wednesday, February 7th. Leerink Partnrs cut shares of Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 7th. StockNews.com lowered shares of Amgen from a “buy” rating to a “hold” rating in a research note on Thursday, March 28th. The Goldman Sachs Group upped their price objective on Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a research note on Wednesday, February 7th. Finally, Oppenheimer reissued an “outperform” rating and issued a $350.00 target price on shares of Amgen in a research report on Thursday, February 1st. Ten research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, Amgen has an average rating of “Moderate Buy” and an average price target of $296.95.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.